Structural model of the Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics.

Malaria, with 300-500 million clinical cases resulting in 1-3 million fatalities a year, is one of the most deadly tropical diseases. As current antimalarial therapeutics become increasingly ineffective due to parasitic resistance, there exists an urgent need to develop and pursue new therapeutic strategies. Recent genome sequencing and molecular cloning projects have identified several enzymes from Plasmodium (P.) falciparum that may represent novel drug targets, including a family of proteins that are homologous to the mammalian cyclin-dependent kinases (CDKs). CDKs are essential for the control of the mammalian cell cycle and, based on the conservation of the CDKs across species, the plasmodial CDKs are expected to play a crucial role in parasitic growth. Here we present a 3D structural model of Pfmrk, a putative human CDK activating kinase (CAK) homolog in P. falciparum. Notable features of the present structural model include: (1) parameterization of the Mg2+ hexacoordination system using ab initio quantum chemical calculations to accurately represent the ATP-kinase interaction; and (2) comparison between the docking scores and measured binding affinities for a series of oxindole-based Pfmrk inhibitors of known activity. Detailed analysis of inhibitor-Pfmrk binding interactions enabled us to identify specific residues (viz. Met66, Met75, Met91, Met94 and Phe143) within the Pfmrk binding pocket that may play an important role in inhibitor binding affinity and selectivity. The availability of this Pfmrk structural model, together with insights gained from analysis of ligand-receptor interactions, should promote the rational design of potent and selective Pfmrk inhibitors as antimalarial therapeutics.

[1]  E. Sausville,et al.  Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.

[2]  N. Waters,et al.  Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development , 2003, Expert opinion on therapeutic targets.

[3]  D. Price,et al.  Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo * , 2001, The Journal of Biological Chemistry.

[4]  S. Prigge,et al.  Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases. , 2001, Biochemical and biophysical research communications.

[5]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[6]  P A Kollman,et al.  Molecular dynamics characterization of the active cavity of carboxypeptidase A and some of its inhibitor adducts , 1992, Proteins.

[7]  B. Kappes,et al.  Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum. , 1994, European journal of biochemistry.

[8]  J. Sachs,et al.  The economic and social burden of malaria , 2002, Nature.

[9]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[10]  Robin Taylor,et al.  A new test set for validating predictions of protein–ligand interaction , 2002, Proteins.

[11]  L. Johnson,et al.  The crystal structure of human CDK7 and its protein recognition properties. , 2004, Structure.

[12]  S. Prigge,et al.  Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum. , 2000, Molecular and biochemical parasitology.

[13]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[14]  G Vriend,et al.  WHAT IF: a molecular modeling and drug design program. , 1990, Journal of molecular graphics.

[15]  Laurent Meijer,et al.  Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. , 2003, Accounts of chemical research.

[16]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[17]  D. Chakrabarti,et al.  PfPK6, a novel cyclin-dependent kinase/mitogen-activated protein kinase-related protein kinase from Plasmodium falciparum. , 2000, The Biochemical journal.

[18]  Apurba K Bhattacharjee,et al.  Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. , 2003, Journal of medicinal chemistry.

[19]  Pauline Ward,et al.  Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote , 2004, BMC Genomics.

[20]  Richard Hughey,et al.  Hidden Markov models for detecting remote protein homologies , 1998, Bioinform..

[21]  Giovanni Soda,et al.  Exploiting the past and the future in protein secondary structure prediction , 1999, Bioinform..

[22]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[23]  J. Chen,et al.  Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. , 1996, European journal of biochemistry.

[24]  D T Jones,et al.  Protein secondary structure prediction based on position-specific scoring matrices. , 1999, Journal of molecular biology.

[25]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[26]  Barbara Kappes,et al.  Activation of a Plasmodium falciparum cdc2-related Kinase by Heterologous p25 and Cyclin H , 2000, The Journal of Biological Chemistry.

[27]  C. Doerig.  Protein kinases as targets for anti-parasitic chemotherapy. , 2004, Biochimica et biophysica acta.

[28]  J. Breman,et al.  The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. , 2001, The American journal of tropical medicine and hygiene.

[29]  Gerd Folkers,et al.  Three‐dimensional model of the cyclin‐dependent kinase 1 (CDK1): Ab initio active site parameters for molecular dynamics studies of CDKS , 2001, Proteins.

[30]  E. Sausville,et al.  Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development , 2002, The Annals of pharmacotherapy.

[31]  C. Chothia,et al.  Intermediate sequences increase the detection of homology between sequences. , 1997, Journal of molecular biology.

[32]  L. Johnson,et al.  The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases , 1999, Nature Cell Biology.

[33]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[34]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[35]  B. Rost,et al.  Prediction of protein secondary structure at better than 70% accuracy. , 1993, Journal of molecular biology.

[36]  R. Steketee,et al.  Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. , 1993, The Journal of infectious diseases.

[37]  R. Young,et al.  Association of Cdk-activating kinase subunits with transcription factor TFIIH , 1995, Nature.

[38]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[39]  J. Shuttleworth.  The regulation and functions of cdk7. , 1995, Progress in cell cycle research.

[40]  M. Noble,et al.  Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. , 2003, Structure.

[41]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[42]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[43]  Carlos Caldas,et al.  Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling , 2004, BMC Genomics.

[44]  J. Stiller,et al.  Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs , 2004, Proceedings. 2004 IEEE Computational Systems Bioinformatics Conference, 2004. CSB 2004..

[45]  Maria Kontoyianni,et al.  Evaluation of docking performance: comparative data on docking algorithms. , 2004, Journal of medicinal chemistry.

[46]  J. Endicott,et al.  Cyclin-dependent kinase homologues of Plasmodium falciparum. , 2002, International journal for parasitology.

[47]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.